948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system
    Journal Article

    Tringale, K. R.; Tyagi, N.; Reyngold, M.; Romesser, P. B.; Wu, A.; O'Reilly, E. M.; Varghese, A. M.; Godoy Scripes, P.; Khalil, D. N.; Park, W.; more...
    Physics and Imaging in Radiation Oncology (2022)

    Fulltext@MSK | Save
  • Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Journal Article

    Calvo, E.; Sessa, C.; Harada, G.; de Miguel, M.; Kahatt, C.; Luepke-Estefan, X. E.; Siguero, M.; Fernandez-Teruel, C.; Cullell-Young, M.; Stathis, A.; more...
    Investigational New Drugs (2022)

    Fulltext@MSK | Save
  • Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity
    Review

    Berretta, M.; Dal Lago, L.; Tinazzi, M.; Ronchi, A.; La Rocca, G.; Montella, L.; Di Francia, R.; Facchini, B. A.; Bignucolo, A.; Montopoli, M.
    Cancers (2022)

    Fulltext@MSK | Save
  • Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial
    Journal Article

    Gounder, M. M.; Razak, A. A.; Somaiah, N.; Chawla, S.; Martin-Broto, J.; Grignani, G.; Schuetze, S. M.; Vincenzi, B.; Wagner, A. J.; Chmielowski, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775
    Journal Article

    Yonemori, K.; Yunokawa, M.; Ushijima, K.; Sakata, J.; Shikama, A.; Minobe, S.; Usami, T.; Enomoto, T.; Takehara, K.; Hasegawa, K.; more...
    Cancer Science (2022)

    Fulltext@MSK | Save
  • Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
    Journal Article

    Paik, P. K.; Luo, J.; Ai, N.; Kim, R.; Ahn, L.; Biswas, A.; Coker, C.; Ma, W.; Wong, P.; Buonocore, D. J.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: Systematic review and meta-analysis
    Review

    Kim, S. D.; Kwag, E. B.; Yang, M. X.; Yoo, H. S.
    International Journal of Molecular Sciences (2022)

    Fulltext@MSK | Save
  • Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis
    Journal Article

    Cadoo, K.; Simpkins, F.; Mathews, C.; Liu, Y. L.; Provencher, D.; McCormick, C.; ElNaggar, A. C.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: Primary results of the randomized phase III IMpassion050 trial
    Journal Article

    Huober, J.; Barrios, C. H.; Niikura, N.; Jarząb, M.; Chang, Y. C.; Huggins-Puhalla, S. L.; Pedrini, J.; Zhukova, L.; Graupner, V.; Eiger, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
    Journal Article

    Park, H.; Shapiro, G. I.; Gao, X.; Mahipal, A.; Starr, J.; Furqan, M.; Singh, P.; Ahrorov, A.; Gandhi, L.; Ghosh, A.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save